Evidence map›Paper›PMID 30555332›Full record

ArticleFrontiers in pharmacology2018

Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site.

Yangguang Liu, Meng Wu, Tianqi Wang, Yongli Xie, Xiangling Cui, Liujun He, Yang He, Xiaoyu Li, Mingliang Liu, Laixing Hu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yangguang LiuKey Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Meng WuKey Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Tianqi WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Yongli XieKey Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Xiangling CuiKey Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Liujun HeInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Yang HeInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Xiaoyu LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Mingliang LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Laixing HuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Shan CenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Jinming ZhouKey Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNZhejiang Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current antiandrogen therapies induce resistant mutations at the hormone binding pocket (HBP) that convert the activity of these agents from antagonist to agonist. Thus, there is a high unmet medical need for the development of novel antiandrogens which circumvent mutation-based resistance. Herein, through the analysis of AR structures with ligands binding to the activation function-2 (AF2) site, we built a combined pharmacophore model.

Indexed as

activation function-2androgen receptorantiandrogencastration-resistant prostate cancerstructural based drug design

Identifiers

PMID30555332
PMCPMC6284051
OpenAlexW2903289577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.